Some genetic abnormalities of multiple myeloma (MM) detected more than two decades ago
remain major prognostic factors. In recent years, the introduction of cutting-edge genomic …

Extramedullary disease of multiple myeloma (EM) remains a treatment challenge even in the
era of new drugs. While many reports analyzing various aspects of EM have been …

Abstract The International Myeloma Working Group consensus updates the definition for
high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities …

PURPOSE To provide evidence-based recommendations on the treatment of multiple
myeloma to practicing physicians and others. METHODS ASCO and Cancer Care Ontario …

Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical
activity in combination with bortezomib and dexamethasone versus bortezomib and …

Patients with relapsed and/or refractory multiple myeloma (RRMM) have poor prognosis.
The STRATUS study assessed safety and efficacy of pomalidomide plus low-dose …

The presence of certain high-risk cytogenetic abnormalities, such as translocations (4; 14)
and (14; 16) and deletion (17p), are known to have a negative impact on survival in multiple …

Background. This retrospective study evaluated the treatment patterns in and overall survival
(OS) of multiple myeloma (MM) patients who were refractory to a proteasome inhibitor (PI) …

Multiple myeloma is one of the most common hematological malignancies, affecting mainly
elderly patients. The treatment landscape for the management of this disease has evolved …

Treatment benefit in multiple myeloma (MM) patients with high‐risk cytogenetics remains
suboptimal. The phase 3 ICARIA‐MM trial (NCT02990338) showed that isatuximab plus …